RESEARCH 研究の報告

2024.5.31

Overcoming acquired resistance following osimertinib administration in EGFR-mutant lung adenocarcinoma.

著者 Kaira K, Imai H, Kagamu H.

Transl Lung Cancer Res. 2024 May 31;13(5):1177-1182. doi: 10.21037/tlcr-24-193. Epub 2024 May 27.

PMID: 38854932 Free PMC article. No abstract available.

2024.5.20

Prior immune checkpoint inhibitors may enhance severe hypersensitivity related to selpercatinib in RET fusion gene-positive lung cancer.

著者 Hashimoto K, Kaira K, Imai H, Shiono A, Kagamu H.

J Chemother. 2024 May 20:1-3. doi: 10.1080/1120009X.2024.2352985. Online ahead of print.

PMID: 38766697

2024.5.20

D-dimer cut-off value for predicting venous thromboembolism at the initial diagnosis in Japanese patients with advanced lung cancer.

著者 Kawakado K, Tsubata Y, Hotta T, Yamasaki M, Ishikawa N, Masuda T, Kubota T, Kobayashi K, Isobe T.

Jpn J Clin Oncol. 2024 May 20:hyae064. doi: 10.1093/jjco/hyae064. Epub ahead of print.

PMID: 38769814.

2024.5.20

Prior immune checkpoint inhibitors may enhance severe hypersensitivity related to selpercatinib in RET fusion gene-positive lung cancer.

著者 Hashimoto K, Kaira K, Imai H, Shiono A, Kagamu H.

J Chemother. 2024 May 20:1-3. doi: 10.1080/1120009X.2024.2352985. Online ahead of print.

PMID: 38766697

2024.5.16

Efficacy and Safety of First-line Pembrolizumab Plus Platinum and Pemetrexed in Elderly Patients with Non-squamous Non-small-cell Lung Cancer.

著者 Wasamoto S, Imai H, Tsuda T, Nagai Y, Kishikawa T, Ono A, Masubuchi K, Umeda Y, Yamada Y, Nakagawa J, Yui T, Taniguchi H, Kaira K, Kagamu H.

Intern Med. 2024 May 16. doi: 10.2169/internalmedicine.3649-24. Online ahead of print.

PMID: 38749728 Free article.

2024.5.16

Progression to Lymph Node Metastasis After Spontaneous Regression of Pulmonary Adenocarcinoma Following Biopsy.

著者 Wasamoto S, Imai H, Tsuda T, Nagai Y, Kishikawa T, Ono A, Masubuchi K, Umeda Y, Yamada Y, Nakagawa J, Yui T, Taniguchi H, Kaira K, Kagamu H.

Intern Med. 2024 May 16. doi: 10.2169/internalmedicine.3649-24. Online ahead of print.

PMID: 38749728

2024.5.19

Real-World Data on Subsequent Therapy for First-Line Osimertinib-Induced Pneumonitis: Safety of EGFR-TKI Rechallenge (Osi-risk Study TORG-TG2101).

著者 Nishioka N, Imai H, Endo M, Notsu A, Doshita K, Igawa S, Yokouchi H, Ninomiya T, Tokito T, Soda S, Fujiwara T, Asao T, Nakamichi S, Kawamura T, Inomata M, Nakashima K, Ito K, Goto Y, Umeda Y, Hirai S, Ushio R, Yokoo K, Takeda T, Fukui T, Ishihara M, Osaki T, Kubo S, Fujiwara T, Yamamoto C, Tsuda T, Tamura N, Hosokawa S, Chihara Y, Ikeda S, Furuya N, Nakahara Y, Miura S, Okamoto H.

Target Oncol. 2024 May;19(3):423-433. doi: 10.1007/s11523-024-01048-x. Epub 2024 Apr 13.

PMID: 38613731 Free PMC article.

2024.5.1

Efficacy and safety of naldemedine for opioid-induced constipation in older patients with cancer: a retrospective study.

著者 Imai H, Fujita Y, Hiruta E, Masuno T, Yamazaki S, Tanaka H, Kamiya T, Sandoh M, Takei S, Arai K, Nishiba H, Mogi J, Koizuka S, Saito T, Obayashi K, Kaira K, Minato K.

Eur J Gastroenterol Hepatol. 2024 May 1;36(5):571-577. doi: 10.1097/MEG.0000000000002746. Epub 2024 Mar 4.

PMID: 38477855

2024.4.6

First-line nivolumab plus ipilimumab with or without chemotherapy for Japanese patients with non-small cell lung cancer: LIGHT-NING study.

著者 Imai H, Kijima T, Azuma K, Kishi K, Saito H, Yamaguchi T, Tanizaki J, Yoneshima Y, Fujita K, Watanabe S, Kitazono S, Fukuhara T, Hataji O, Toi Y, Mizutani H, Hamakawa Y, Maemondo M, Ohsugi T, Suzuki K, Horinouchi H, Ohe Y.

Jpn J Clin Oncol. 2024 Apr 6;54(4):452-462. doi: 10.1093/jjco/hyad195.

PMID: 38271158 Free PMC article.

2024.4.3

Clinical Outcome of Nivolumab Plus Ipilimumab in Patients with Locally Advanced Non-Small-Cell Lung Cancer with Relapse after Concurrent Chemoradiotherapy followed by Durvalumab.

著者 Mouri A, Watanabe S, Tokito T, Nagai Y, Saida Y, Imai H, Yamaguchi O, Kobayashi K, Kaira K, Kagamu H.

Cancers (Basel). 2024 Apr 3;16(7):1409. doi: 10.3390/cancers16071409.

PMID: 38611087 Free PMC article.

2024.4.1

Immunotherapy or Chemoimmunotherapy in Older Adults With Advanced Non-Small Cell Lung Cancer.

著者 Tsukita Y, Tozuka T, Kushiro K, Hosokawa S, Sumi T, Uematsu M, Honjo O, Yamaguchi O, Asao T, Sugisaka J, Saito G, Shiihara J, Morita R, Katakura S, Yasuda T, Hisakane K, Miyauchi E, Morita S, Kobayashi K, Asahina H.

JAMA Oncol. 2024 Apr 1;10(4):439-447. doi: 10.1001/jamaoncol.2023.6277.

PMID: 38451530; PMCID: PMC10921348.

2024.4.1

Metabolic Tumor Volume as Significant Predictor for Chemotherapy Containing PD-L1 Blocker in Extensive Stage Small Cell Lung Cancer.

著者 Hashimoto K, Kaira K, Imai H, Miura YU, Shiono A, Mouri A, Yamaguchi OU, Kobayashi K, Kagamu H, Kuji I.

Anticancer Res. 2024 Apr;44(4):1541-1551. doi: 10.21873/anticanres.16951.

PMID: 38537960